Characterization of inflammatory profile by breath analysis in chronic coronary syndromes.
Aged
Biomarkers
/ metabolism
Breath Tests
/ instrumentation
Chronic Disease
Coronary Angiography
Cross-Sectional Studies
Electronic Nose
Female
Humans
Inflammation Mediators
/ metabolism
Male
Myocardial Ischemia
/ diagnostic imaging
Percutaneous Coronary Intervention
Predictive Value of Tests
Prognosis
Severity of Illness Index
Volatile Organic Compounds
/ metabolism
Journal
Journal of cardiovascular medicine (Hagerstown, Md.)
ISSN: 1558-2035
Titre abrégé: J Cardiovasc Med (Hagerstown)
Pays: United States
ID NLM: 101259752
Informations de publication
Date de publication:
Sep 2020
Sep 2020
Historique:
entrez:
3
8
2020
pubmed:
3
8
2020
medline:
8
6
2021
Statut:
ppublish
Résumé
Exhaled breath contains thousands of volatile organic compounds (VOCs) produced during various metabolic processes both in health and disease.Analysis of breath with electronic nose BIONOTE-V allows modifications of exhaled VOCs to be studied, which are clinically recognized to be a marker for several disorders, including heart failure. New noninvasive tests based on VOCs analysis might be a useful tool for early detection of chronic coronary syndromes (CCS). Exhaled air was collected and measured in individuals with an indication to perform invasive coronary angiography (ICA). All patients' samples were obtained before ICA. Analysis with BIONOTE-V was performed in a total cohort of 42 patients consecutively enrolled, of whom 19 did not require myocardial revascularization and 23 with indication for myocardial revascularization. BIONOTE-V was able to correctly identify 18 out of 23 patients affected by severe coronary artery disease (sensitivity = 78.3% and specificity = 68.4%). Our predicted model had a tight correlation with SYNTAX score (error of the BIONOTE-V = 15). CCS patients have a distinctive fingerprint of exhaled breath, and analysis by BIONOTE-V has the potential for identifying these patients. Moreover, it seems that this technique can correctly identify patients according to anatomical disease severity at ICA. If the preliminary data of this proof of concept study will be confirmed, this rapid and noninvasive diagnostic tool able to identify CCS might have an impact in routine clinical practice.
Identifiants
pubmed: 32740499
doi: 10.2459/JCM.0000000000001032
pii: 01244665-202009000-00010
doi:
Substances chimiques
Biomarkers
0
Inflammation Mediators
0
Volatile Organic Compounds
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
675-681Références
Benjamin EJ, Blaha MJ, Chiuve SE, et al. Heart disease and stroke statistics-2017 update: a report from the American Heart Association. Circulation 2017; 135:e146–e603.
Knuuti J, Wijns W, Saraste A, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes: the Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC). Eur Heart J 2019.
Wu MY, Li CJ, Hou MF, Chu PY. New insights into the role of inflammation in the pathogenesis of atherosclerosis. Int J Mol Sci 2017; 18:2034.
Gerszten RE, Wang TJ. The search for new cardiovascular biomarkers. Nature 2008; 451:949–952.
Uydu HA, Bostan M, Yilmaz A, et al. Comparision of inflammatory biomarkers for detection of coronary stenosis in patients with stable coronary artery disease. Eur Rev Med Pharmacol Sci 2013; 17:112–118.
Rubini Gimenez M, Twerenbold R, Mueller C. Beyond cardiac troponin: recent advances in the development of alternative biomarkers for cardiovascular disease. Expert Rev Mol Diagn 2015; 15:547–556.
Mair J, Jaffe AS. Biomarker tests for risk assessment in coronary artery disease: will they change clinical practice? Mol Diagn Ther 2014; 18:5–15.
Rhee EP, Gerszten RE. Metabolomics and cardiovascular biomarker discovery. Clin Chem 2012; 58:139–147.
Cikach FS Jr, Dweik RA. Cardiovascular biomarkers in exhaled breath. Prog Cardiovasc Dis 2012; 55:34–43.
van de Kant KD, van der Sande LJ, Jobsis Q, van Schayck OC, Dompeling E. Clinical use of exhaled volatile organic compounds in pulmonary diseases: a systematic review. Respir Res 2012; 13:117.
De Vincentis A, Pennazza G, Santonico M, et al. Breath-print analysis by e-nose for classifying and monitoring chronic liver disease: a proof-of-concept study. Sci Rep 2016; 6:25337.
Cazzola M, Segreti A, Capuano R, et al. Analysis of exhaled breath fingerprints and volatile organic compounds in COPD. COPD Res Pract 2015; 1:7.
Samara MA, Tang WH, Cikach F Jr, et al. Single exhaled breath metabolomic analysis identifies unique breathprint in patients with acute decompensated heart failure. J Am Coll Cardiol 2013; 61:1463–1464.
Incalzi RA, Pennazza G, Scarlata S, et al. Reproducibility and respiratory function correlates of exhaled breath fingerprint in chronic obstructive pulmonary disease. PLoS One 2012; 7:e45396.
Sianos G, Morel MA, Kappetein AP, et al. The SYNTAX Score: an angiographic tool grading the complexity of coronary artery disease. EuroIntervention 2005; 1:219–227.
Genereux P, Palmerini T, Caixeta A, et al. Quantification and impact of untreated coronary artery disease after percutaneous coronary intervention: the residual SYNTAX (Synergy Between PCI with Taxus and Cardiac Surgery) score. J Am Coll Cardiol 2012; 59:2165–2174.
Farooq V, Girasis C, Magro M, et al. The CABG SYNTAX Score: an angiographic tool to grade the complexity of coronary disease following coronary artery bypass graft surgery: from the SYNTAX Left Main Angiographic (SYNTAX-LE MANS) substudy. EuroIntervention 2013; 8:1277–1285.
Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J 2005; 26:319–338.
Wanger J, Clausen JL, Coates A, et al. Standardisation of the measurement of lung volumes. Eur Respir J 2005; 26:511–522.
Kunos L, Bikov A, Lazar Z, et al. Evening and morning exhaled volatile compound patterns are different in obstructive sleep apnoea assessed with electronic nose. Sleep Breath 2015; 19:247–253.
Santonico M, Pennazza G, Grasso S, D’Amico A, Bizzarri M. Design and test of a biosensor-based multisensorial system: a proof of concept study. Sensors (Basel) 2013; 13:16625–16640.
Pennazza G, Antonelli Incalzi SM, Scarlata R, Chiurco S, Vernile D, D’Amico CA. Measure chain for exhaled breath collection and analysis: a novel approach suitable for frail respiratory patients. Sensors Actuat B Chem 2014; 204:578–587.
Westerhuis HH, Smit S, Vis DJ, Smilde AK, van Velzen EJ, van Duijnhoven PM, van Dorsten A. Assessment of PLSDA cross validation. Metabolomics 2008; 4:81–89.
McCarthy CP, McEvoy JW, Januzzi JL Jr. Biomarkers in stable coronary artery disease. Am Heart J 2018; 196:82–96.
Basanta M, Ibrahim B, Dockry R, et al. Exhaled volatile organic compounds for phenotyping chronic obstructive pulmonary disease: a cross-sectional study. Respir Res 2012; 13:72.
Marcondes-Braga FG, Batista GL, Bacal F, Gutz I. Exhaled breath analysis in heart failure. Curr Heart Fail Rep 2016; 13:166–171.
Mazzatenta A, Di Giulio C, Pokorski M. Pathologies currently identified by exhaled biomarkers. Respir Physiol Neurobiol 2013; 187:128–134.
Scarlata S, Pennazza G, Santonico M, Pedone C, Antonelli Incalzi R. Exhaled breath analysis by electronic nose in respiratory diseases. Expert Rev Mol Diagn 2015; 15:933–956.
Wilson AD, Baietto M. Advances in electronic-nose technologies developed for biomedical applications. Sensors (Basel) 2011; 11:1105–1176.
D’Amico A, Ferri G, Zompanti A. Sensor Systems for Breathprinting: A Review of the Current Technologies for Exhaled Breath Analysis Based on a Sensor Array With the Aim of Integrating Them in a Standard and Shared Procedure. In: Pennazza G, Santonico M. Breath Analysis. 1st ed. Academic Press, 2019: 49-79
Rocco R, Incalzi RA, Pennazza G, et al. BIONOTE e-nose technology may reduce false positives in lung cancer screening programmesdagger. Eur J Cardiothorac Surg 2016; 49:1112–1117. discussion 7.
Di Natale C, Paolesse R, Martinelli E, Capuano R. Solid-state gas sensors for breath analysis: a review. Anal Chim Acta 2014; 824:1–17.
Einoch Amor R, Nakhleh MK, Barash O, Haick H. Breath analysis of cancer in the present and the future. Eur Respir Rev 2019; 28:190002.
Christiansen A, Davidsen JR, Titlestad I, Vestbo J, Baumbach J. A systematic review of breath analysis and detection of volatile organic compounds in COPD. J Breath Res 2016; 10:034002.
Azim A, Barber C, Dennison P, Riley J, Howarth P. Exhaled volatile organic compounds in adult asthma: a systematic review. Eur Respir J 2019; 54:1900056.
Finamore P, Scarlata S, Cardaci V, Incalzi RA. Exhaled breath analysis in obstructive sleep apnea syndrome: a review of the literature. Medicina (Kaunas) 2019; 55:538.
De Marzo V, D’Amario D, Galli M, Vergallo R, Porto I. High-risk percutaneous coronary intervention: how to define it today? Minerva Cardioangiol 2018; 66:576–593.
Akin F, Ayca B, Kose N, et al. Relation of platelet indices to severity of coronary artery disease in patients undergoing primary percutaneous coronary intervention. Perfusion 2016; 31:216–222.
He S, Lei W, Li J, et al. Relation of platelet parameters with incident cardiovascular disease (The Dongfeng-Tongji Cohort Study). Am J Cardiol 2019; 123:239–248.
Montuschi P, Santonico M, Mondino C, et al. Diagnostic performance of an electronic nose, fractional exhaled nitric oxide, and lung function testing in asthma. Chest 2010; 137:790–796.